Here is an update on the DECAAF study that Dr. Nassir Marrouche presented at the European Society of Cardiology in Amsterdam today. According to Dr. Marrouche, the amount of fibrosis (scar tissue created in the heart by atrial fibrillation), as measured on pre-ablation MRIs (magnetic resonance imaging), predicts the success of catheter ablations for atrial …
Read More
As reported at the European Society of Cardiology in Amsterdam, among patients with 0-2 stroke risk factors, those with atrial fibrillation had a three-fold risk of stroke over those who didn’t have afib. But that difference declined as the number of risk factors increased. The risk of stroke was high in those with 3 or …
Read More
We’re finally getting a glimpse into what to expect from edoxaban, the 4th new anticoagulant medication. At the European Society of Cardiology in Amsterdam, it was reported that edoxaban was safer--in other words, had less bleeding--than warfarin for those with deep vein thrombosis (blood clots in the legs) or pulmonary embolism (blood clots in the …
Read More
This confirms what we already knew... As reported today at the European Society of Cardiology in Amsterdam: "Women with AF receive less anticoagulation treatment than men despite the fact that they are at greater risk of stroke. The new CHA2DS2-VASc score should be used more stringently, especially in women, to optimise their treatment. Treatment of …
Read More